Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jun:178:104805.
doi: 10.1016/j.antiviral.2020.104805. Epub 2020 Apr 21.

Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses

Mike Bray, Craig Rayner, François Noël, David Jans, Kylie Wagstaff
Editorial

Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses

Mike Bray et al. Antiviral Res. 2020 Jun.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Simulated mean concentration-time profile of ivermectin in plasma (black line) and lung tissue (blue line) following 600 μg/kg dose daily for 3 days. The 5th and 95th percentiles are also shown. The red-line is the IC50 (2μM) against SARS-CoV-2 determined in vitro by Caly et al. (2020).
See this image and copyright information in PMC

Comment on

References

    1. Baraka O.Z. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur. J. Clin. Pharmacol. 1996;50(5):407–410. - PubMed
    1. Caly L. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir. Res. 2020 doi: 10.1016/j.antiviral.2020.104787. - DOI - PMC - PubMed
    1. Crump A., Omura S. Ivermectin, 'wonder drug' from Japan: the human use perspective. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2011;87(2):13–28. - PMC - PubMed
    1. Guzzo C.A. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J. Clin. Pharmacol. 2002;42(10):1122–1133. - PubMed
    1. Merck . 1996. Mectizan NDA 050742.